Medifocus Inc. Announces Extension of Warrants

Medifocus Inc. (Medifocus or the Company) (TSX VENTURE:MFS)(OTCQX:MDFZF) is
pleased to announce that it has applied to the TSX Venture Exchange (the
Exchange) to extend the expiry date of 13,056,997 outstanding common share
purchase warrants issued pursuant to the private placement announced November
30, 2012 and to extend the expiry date of 22,196,795 outstanding common share
purchase warrants issued pursuant to the private placement announced July 6,
2012 by one year. Both sets of warrants entitle the holder thereof to acquire
one common share of Medifocus at a price of $0.20.


If the Exchange approves the extensions, the Company will be permitted to extend
the term of the warrants from January 14, 2015 to January 14, 2016, in the first
instance and from September 21, 2014 to September 21, 2015, in the second
instance. All other terms and conditions of the Warrants will remain unchanged
and in full force and effect.


On June 6, 2014, the Company received approval to extend the expiry date of
40,567,253 outstanding common share purchase warrants to June 15, 2015, as
previously announced. These are comprised of 18,367,253 outstanding common share
purchase warrants issued pursuant to the private placement announced June 8,
2012 and 22,200,000 outstanding common share purchase warrants issued pursuant
to the private placement announced Jun 21, 2012. Both sets of warrants entitle
the holder thereof to acquire one common share of Medifocus at a price of $0.20.


About Medifocus, Inc.

Medifocus owns two fully developed technology platforms with comprehensive
United States and international patent protection: (i) The Endo-thermotherapy
Platform-a catheter-basis focused heat technology platform that utilizes natural
body openings to deliver precise microwave thermotherapy to the diseased sites.
The United States Food and Drug Administration (FDA) approved Prolieve
Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH)
was developed based on the Endo-thermotherapy and is currently generating
revenue; and (ii) the Adaptive Phased Array (APA) Microwave Focusing Platform,
invented by the Massachusetts Institute of Technology, licensed to Medifocus,
directs precisely focused microwave energy at tumor center to induce shrinkage
or eradication of tumors without undue harm to surrounding tissue. Medifocus'
APA 1000 Breast Cancer Treatment System, developed from the APA technology
platform, has received approval from the FDA and Health Canada to conduct the
pivotal Phase III clinical trials. Medifocus believes that these two technology
platforms can provide the design basis for the development of multiple cancer
treatment systems for surface, subsurface and deep seated localized and regional
cancers. Please visit www.medifocusinc.com, www.prolieve.com and
http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for
more details.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Medifocus Contact:
John Mon, COO
Medifocus, Inc.
410-290-5734
[e-mail]


Investor Relations Contact:
Robert Giordano
Consulting for Strategic Growth 1
917-327-3938
[e-mail]